DK0591392T3 - Farmaceutiske formuleringer af osteogene proteiner - Google Patents

Farmaceutiske formuleringer af osteogene proteiner

Info

Publication number
DK0591392T3
DK0591392T3 DK92914339.4T DK92914339T DK0591392T3 DK 0591392 T3 DK0591392 T3 DK 0591392T3 DK 92914339 T DK92914339 T DK 92914339T DK 0591392 T3 DK0591392 T3 DK 0591392T3
Authority
DK
Denmark
Prior art keywords
pct
pharmaceutical formulations
osteogenic proteins
date
sec
Prior art date
Application number
DK92914339.4T
Other languages
English (en)
Inventor
Eyal Ron
Thomas J Turek
Benjamin S Isaacs
Himakshi Patel
Richard A Kenley
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Inst filed Critical Genetics Inst
Application granted granted Critical
Publication of DK0591392T3 publication Critical patent/DK0591392T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/28—Bones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
DK92914339.4T 1991-06-21 1992-06-22 Farmaceutiske formuleringer af osteogene proteiner DK0591392T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71872191A 1991-06-21 1991-06-21

Publications (1)

Publication Number Publication Date
DK0591392T3 true DK0591392T3 (da) 1996-09-30

Family

ID=24887221

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92914339.4T DK0591392T3 (da) 1991-06-21 1992-06-22 Farmaceutiske formuleringer af osteogene proteiner

Country Status (15)

Country Link
US (1) US5597897A (da)
EP (1) EP0591392B1 (da)
JP (1) JP3351525B2 (da)
KR (1) KR0145278B1 (da)
AT (1) ATE142460T1 (da)
AU (1) AU663328B2 (da)
CA (1) CA2111199C (da)
DE (1) DE69213739T2 (da)
DK (1) DK0591392T3 (da)
ES (1) ES2094359T3 (da)
FI (1) FI109274B (da)
GR (1) GR3021627T3 (da)
MX (1) MX9203083A (da)
NO (2) NO934573D0 (da)
WO (1) WO1993000050A1 (da)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705485A (en) * 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
US7056882B2 (en) 1991-03-11 2006-06-06 Curis, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US5674844A (en) * 1991-03-11 1997-10-07 Creative Biomolecules, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US5171579A (en) * 1991-10-11 1992-12-15 Genetics Institute, Inc. Formulations of blood clot-polymer matrix for delivery of osteogenic proteins
US5385887A (en) * 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
US6027919A (en) 1993-12-07 2000-02-22 Genetics Institute, Inc. BMP-12 and BMP-13 proteins and DNA encoding them
AU689184B2 (en) 1993-12-07 1998-03-26 Genetics Institute, Llc BMP-12, BMP-13 and tendon-inducing compositions thereof
WO1995024210A1 (en) 1994-03-08 1995-09-14 Genetics Institute, Inc. Methods and compositions for treatment of periodontal disease and repair of periodontal lesions
CA2712304C (en) 1994-06-10 2011-10-25 United States Surgical Corporation Recombinant chimeric proteins and methods of use thereof
US5520923A (en) * 1994-09-19 1996-05-28 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
FR2726571B1 (fr) * 1994-11-03 1997-08-08 Izoret Georges Colle biologique, procede de preparation et dispositif d'application pour colle biologique, et durcisseurs pour colle biologique
US20060280774A1 (en) * 1995-06-02 2006-12-14 Allergan, Inc. Compositions and methods for treating glaucoma
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
HU222664B1 (hu) 1995-06-05 2003-09-29 Genetics Institute, Llc Csont morfogenetikus protein (BMP) alkalmazása csont és ín vagy szalag funkcionális összeköttetésének regenerálására
US6352972B1 (en) * 1995-06-06 2002-03-05 Marcel E. Nimni Bone morphogenetic proteins and their use in bone growth
US5674292A (en) 1995-06-07 1997-10-07 Stryker Corporation Terminally sterilized osteogenic devices and preparation thereof
JPH09143093A (ja) * 1995-11-17 1997-06-03 Hoechst Japan Ltd 軟骨・骨誘導性修復用材料
KR20000064752A (ko) 1996-03-22 2000-11-06 더 제네랄 호스피탈 코포레이션 중추신경계허혈또는외상의발현후폴리펩티드성장인자를투여하는방법
US5700774A (en) * 1996-03-26 1997-12-23 Genetics Institute, Inc. Compositions comprising bone morphogenic proteins and truncated parathyroid hormone related peptide, and methods of inducing cartilage by administration of same
US6492508B1 (en) 1996-06-03 2002-12-10 United States Surgical Corp. A Division Of Tyco Healthcare Group Nucleic acids encoding extracellular matrix proteins
GB9621825D0 (en) * 1996-10-19 1996-12-11 Andaris Ltd Microparticles and their use as therapeutic vehicles
WO1998031788A1 (en) * 1997-01-21 1998-07-23 Genetics Institute, Inc. Injectable formulations for treatment of osteoporotic bone
US20040132653A1 (en) * 1997-01-30 2004-07-08 Biopharm Gmbh Lyophilized composition of bone morphogenetic factor human MP52
PL189381B1 (pl) * 1997-01-30 2005-07-29 Bioph Biotech Entw Pharm Gmbh Rekonstytuowany MP52 oraz sposób wytwarzania rekonstytuowanego MP52
US20010016646A1 (en) 1998-03-20 2001-08-23 David C. Rueger Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects
US7041641B2 (en) 1997-03-20 2006-05-09 Stryker Corporation Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
EP0902036A1 (en) 1997-09-05 1999-03-17 Roche Diagnostics GmbH Peptide containing an arginine mimetic for the treatment of osteoporosis, their production, and drugs containing these compounds
FR2764514B1 (fr) * 1997-06-13 1999-09-03 Biopharmex Holding Sa Implant injectable en sous-cutane ou intradermique a bioresorbabilite controlee pour la chirurgie reparatrice ou plastique et la dermatologie esthetique
DE19726412A1 (de) * 1997-06-21 1998-12-24 Merck Patent Gmbh Implantatmaterial mit einer Träger-Wirkstoff-Kombination
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
DE69840361D1 (de) 1997-07-30 2009-01-29 Univ Emory Neue knochenmineralisierungsproteine, dna, vektoren, expressionssysteme
EP0906759A1 (de) 1997-10-02 1999-04-07 Roche Diagnostics GmbH Neue Osteoblastenspezifische Mitogene: Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6911553B1 (en) 1997-10-02 2005-06-28 Roche Diagnostics Gmbh Osteoblast-specific mitogens and drugs containing such compounds
US6767892B1 (en) * 1997-11-07 2004-07-27 Chrion Corporation Compositions providing for increased IGF-I solubility
IL136230A0 (en) 1997-11-28 2001-05-20 Roche Diagnostics Gmbh An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes
WO1999030632A1 (en) * 1997-12-18 1999-06-24 Comfort Biomedical, Inc. Bone augmentation for prosthetic implants and the like
US6214049B1 (en) 1999-01-14 2001-04-10 Comfort Biomedical, Inc. Method and apparatus for augmentating osteointegration of prosthetic implant devices
US20030147860A1 (en) 2002-02-07 2003-08-07 Marchosky J. Alexander Compositions and methods for forming and strengthening bone
US6849255B2 (en) 1998-08-18 2005-02-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for enhancing cartilage repair
US6630457B1 (en) * 1998-09-18 2003-10-07 Orthogene Llc Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same
EP1120122A1 (en) * 1998-09-30 2001-08-01 Takeda Chemical Industries, Ltd. Bone repair materials/artificial bone compositions
US6663870B2 (en) 1998-12-07 2003-12-16 Zymogenetics, Inc. Methods for promoting growth of bone using zvegf3
DE19906096A1 (de) 1999-02-13 2000-08-17 Walter Sebald Protein mit einem Heparin-bindenden Epitop
US6468543B1 (en) 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
WO2001000792A1 (en) 1999-06-29 2001-01-04 Marchosky J Alexander Compositions and methods for forming and strengthening bone
WO2001057083A1 (en) * 2000-02-04 2001-08-09 Zymogenetics, Inc. Methods for promoting growth of bone, ligament, and cartilage using zvegf4
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
CA2426298A1 (en) * 2000-10-24 2002-05-02 Sdgi Holdings, Inc. Osteogenic packing device and method
US6699493B2 (en) * 2000-11-29 2004-03-02 Oculex Pharmaceuticals, Inc. Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US6949251B2 (en) * 2001-03-02 2005-09-27 Stryker Corporation Porous β-tricalcium phosphate granules for regeneration of bone tissue
CA2445523A1 (en) 2001-04-30 2002-11-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Composite scaffolds and methods using same for generating complex tissue grafts
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
WO2003066000A2 (en) * 2002-02-08 2003-08-14 Wyeth Formulation comprising bioactive agents and method of using same
EP1478415A1 (en) * 2002-02-22 2004-11-24 Biomatera Inc. Biodegradable bone implant
EP1551955A4 (en) 2002-07-16 2006-11-29 Yissum Res Dev Co METHOD FOR IMPLANTING MESENCHYMAL STEM CELLS FOR TISSUE PAIRING AND FORMATION
US20040023322A1 (en) * 2002-08-01 2004-02-05 Goodheart Clyde R. Method of producing non-recombinant BMP-2 and use thereof
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20050003007A1 (en) * 2003-07-02 2005-01-06 Michele Boix Method of sterilization of polymeric microparticles
US7141544B2 (en) * 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
EP1706095B1 (en) 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20050244462A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US20050244461A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050244478A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Anti-excititoxic sustained release intraocular implants and related methods
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
BRPI0510485A (pt) 2004-04-30 2007-11-13 Allergan Inc implantes inibidores de tirosina cinase intravìtreos biodegradáveis
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US7993634B2 (en) * 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8591885B2 (en) * 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8455656B2 (en) 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
EP1793875B9 (en) 2004-06-16 2010-09-08 Affinergy, Inc. Ifbm's to promote attachment of target analytes
US8512730B2 (en) 2004-07-12 2013-08-20 Isto Technologies, Inc. Methods of tissue repair and compositions therefor
WO2006033698A2 (en) * 2004-07-12 2006-03-30 Isto Technologies, Inc. Tissue matrix system
AU2005271700B2 (en) * 2004-07-12 2010-11-11 Allergan, Inc. Opthalmic compositions and methods for treating ophthalmic conditions
US20060258578A1 (en) * 2005-05-10 2006-11-16 The University Of Zurich Pharmaceutical composition
US20060286171A1 (en) * 2005-06-17 2006-12-21 Tianhong Zhou Bone morphogenetic protein formulations
ES2528272T3 (es) * 2005-12-07 2015-02-06 Isto Technologies Inc. Métodos de reparación de cartílago
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
AU2007254824A1 (en) 2006-06-02 2007-12-13 Wyeth Use of proteins and peptides of the TGF-beta superfamily for purification and therapeutic methods
US7754689B2 (en) 2006-06-02 2010-07-13 Wyeth Llc Finger-1 peptide analogs of the TGF-β superfamily
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8802128B2 (en) * 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
DE102006060958A1 (de) * 2006-12-20 2008-06-26 Jennissen, Herbert P., Prof. Dr. Verfahren zur Herstellung einer Polymermatrix, daraus bestehende Implantate sowie deren Verwendung
US7911053B2 (en) * 2007-04-19 2011-03-22 Marvell World Trade Ltd. Semiconductor packaging with internal wiring bus
EP2144624A1 (en) 2007-05-15 2010-01-20 Stryker Corporation Concentrated protein preparations of bone morphogenetic proteins and methods of use thereof
DE102007051914A1 (de) * 2007-10-29 2009-05-07 Herbert Prof. Dr. Jennissen Verfahren zur Herstellung von mit Wachstumsfaktoren beladenen Partikeln sowie die so erhaltenen Partikel
US8764350B2 (en) 2008-06-05 2014-07-01 Alstom Technology Ltd Conveyor for transporting powder, and a method for conveying powder
NZ628266A (en) 2009-11-09 2016-02-26 Allergan Inc Compositions and methods for stimulating hair growth
DK2569342T3 (da) 2010-05-11 2022-04-19 Howmedica Osteonics Corp Multivalente organofosformetalforbindelser og interpenetrerende polymerklæbemiddelnetværkssammensætninger og fremgangsmåder
JP2012082180A (ja) * 2010-10-14 2012-04-26 Nagoya Univ 骨再生用自己組織化ペプチドハイドロゲル
WO2012158527A2 (en) 2011-05-13 2012-11-22 Howmedica Osteonics Organophosphorous & multivalent metal compound compositions & methods
IN2014DN09621A (da) * 2012-05-14 2015-07-31 Teijin Ltd
US10245306B2 (en) 2012-11-16 2019-04-02 Isto Technologies Ii, Llc Flexible tissue matrix and methods for joint repair
AU2014216112B2 (en) 2013-02-15 2019-02-21 Allergan, Inc. Sustained drug delivery implant
AU2015233396B2 (en) 2014-03-20 2020-01-30 Stayble Therapeutics Ab A composition for use in the treatment of intervertebral disc-related pain
US10179191B2 (en) 2014-10-09 2019-01-15 Isto Technologies Ii, Llc Flexible tissue matrix and methods for joint repair
US10195305B2 (en) * 2015-03-24 2019-02-05 Orthovita, Inc. Bioactive flowable wash-out resistant bone graft material and method for production thereof
WO2017046030A1 (en) 2015-09-14 2017-03-23 Stayble Therapeutics Ab A composition for use in the treatment of intervertebral disc-related pain
JP6901721B2 (ja) * 2017-03-30 2021-07-14 国立大学法人東海国立大学機構 骨髄止血剤
KR102066392B1 (ko) 2017-11-14 2020-01-16 한국치아은행 주식회사 골 이식용 복합체 제조방법 및 이에 의해 제조된 골 이식용 복합체
CN109125791B (zh) * 2018-09-29 2019-08-30 广州贝奥吉因生物科技有限公司 一种具有促进骨修复功能的可吸收骨蜡及制备方法
EP3936165A1 (en) * 2020-07-10 2022-01-12 MedPark Co., Ltd. Method for preparing bone graft composition and bone graft composition

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3407076A (en) * 1964-08-28 1968-10-22 Hercules Inc Protein-polymer complexes and process
GB1332505A (en) * 1970-10-16 1973-10-03 Ethicon Inc Sutures and other surgical aids
US3991766A (en) * 1973-05-31 1976-11-16 American Cyanamid Company Controlled release of medicaments using polymers from glycolic acid
US4033938A (en) * 1974-01-21 1977-07-05 American Cyanamid Company Polymers of unsymmetrically substituted 1,4-dioxane-2,5-diones
EP0140255B1 (en) * 1983-10-14 1991-05-15 Sumitomo Pharmaceuticals Company, Limited Sustained-release injections
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4563489A (en) * 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
US4637931A (en) * 1984-10-09 1987-01-20 The United States Of America As Represented By The Secretary Of The Army Polyactic-polyglycolic acid copolymer combined with decalcified freeze-dried bone for use as a bone repair material
DE3678308D1 (de) * 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
JPS62223112A (ja) * 1986-03-25 1987-10-01 Rooto Seiyaku Kk 歯周病治療剤
IL83003A (en) * 1986-07-01 1995-07-31 Genetics Inst Factors that soak bone formation
US4877864A (en) * 1987-03-26 1989-10-31 Genetics Institute, Inc. Osteoinductive factors
DE3624171A1 (de) * 1986-07-17 1988-01-21 Bosch Gmbh Robert Heiz- und/oder klimaanlage fuer kraftfahrzeuge
NL8702563A (nl) * 1987-10-28 1989-05-16 Cca Biochem B V Polymeer lactide, werkwijze voor het bereiden van een dergelijk polymeer lactide, alsmede een samenstelling, die een dergelijk polymeer lactide bevat.
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US4975526A (en) * 1989-02-23 1990-12-04 Creative Biomolecules, Inc. Bone collagen matrix for zenogenic implants
US5108753A (en) * 1988-04-08 1992-04-28 Creative Biomolecules Osteogenic devices
KR900700617A (ko) * 1988-04-08 1990-08-16 브루스 엠. 에이센 뼈 및 연골 유도 조성물
EP0372031B1 (en) * 1988-04-08 1996-09-11 Stryker Corporation Biosynthetic osteogenic proteins and osteogenic devices containing them
WO1990009783A1 (en) * 1989-02-22 1990-09-07 Massachusetts Institute Of Technology Delivery system for controlled release of bioactive factors
EP0476045B1 (en) * 1989-06-05 1996-08-28 Massachusetts Institute Of Technology Bioerodible polymers for drug delivery in bone
CA2024196A1 (en) * 1990-06-13 1991-12-14 Thomas M. S. Chang Porous microbead permeable to macromolecules having immobilized therein at least one biological particulate
EP0489743A1 (en) * 1990-07-03 1992-06-17 Vipont Pharmaceutical, Inc. Intragingival delivery systems for treatment of periodontal disease

Also Published As

Publication number Publication date
NO934573D0 (no) 1993-12-13
CA2111199C (en) 2008-08-05
FI935732A (fi) 1993-12-20
DE69213739D1 (de) 1996-10-17
FI109274B (fi) 2002-06-28
MX9203083A (es) 1994-08-31
GR3021627T3 (en) 1997-02-28
AU2254292A (en) 1993-01-25
JP3351525B2 (ja) 2002-11-25
NO307402B1 (no) 2000-04-03
JPH06508777A (ja) 1994-10-06
EP0591392B1 (en) 1996-09-11
AU663328B2 (en) 1995-10-05
FI935732A0 (fi) 1993-12-20
NO934573L (no) 1993-12-13
ATE142460T1 (de) 1996-09-15
EP0591392A1 (en) 1994-04-13
CA2111199A1 (en) 1993-01-07
DE69213739T2 (de) 1997-02-20
ES2094359T3 (es) 1997-01-16
WO1993000050A1 (en) 1993-01-07
KR0145278B1 (ko) 1998-07-15
US5597897A (en) 1997-01-28

Similar Documents

Publication Publication Date Title
DK0591392T3 (da) Farmaceutiske formuleringer af osteogene proteiner
NO922026L (no) Formuleringer med forsinket frigjoering
KR890700366A (ko) 외과용 재료 및 장치
AU5118990A (en) Compositions for the sustained-release of chlorhexidine
ATE189611T1 (de) Zusammensetzungen, die eine blutgerinnselpolymermatrix zur verabreichung von osteogenen proteinen enthalten
DE69432025D1 (de) Formulierungen mit verzögerter freisetzung zur abgabe von metoprolol über 24 stunden
ATE177114T1 (de) Polypeptide und daraus hergestellte, gegen hiv wirksame substanzen
BR9611175A (pt) Compostos ou suas composições e uso dos mesmo
ATE97930T1 (de) Biologisch abbaubare poly-(hydroxyalkyl)aminodicarbons|ure-derivate, verfahren zu ihrer herstellung und verwendung derselben fuer depotzubereitungen mit kontrollierter wirkstoffabgabe.
IL124674A0 (en) Piperazine derivatives pharmaceutical compositions containing the same and use thereof
DE69934582D1 (de) Delavirdin tablettenformulierung
ES2131528T3 (es) Nuevos polipeptidos y su uso.
SE8804628D0 (sv) New compounds
ATE281155T1 (de) Medikamentöse verabreichung von proteinen aus polymergemischen
ATE189262T1 (de) Interferon-alpha/beta bindendes protein, seine herstellung und seine enthaltende pharmazeutische zusammensetzungen
EP0820770A3 (de) Arzneimittel zur Behandlung von Neuropathien, das ein lipidlösliches Thiamin und ein Antioxidans enthält
FI964448A (fi) Uusi biologisesti aktiivinen peptidi ja sen valmistus
HRP20020071B1 (en) Pharmaceutical composition and preparation thereof
AU7533394A (en) Antiacid pharmaceutical composition in the form of a suspension based on sucralphate gel